Clinical Trial Update: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating ixazomib in autologous stem cell transplant for relapsed multiple myeloma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)

Snippet

Sponsor: University of Leeds | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING